Management of crizotinib therapy for ALK-rearranged non-small cell lung carcinoma: An expert consensus

Lung Cancer

Volumn 87, Issue 2, 2015, Pages 89-95

  Cappuzzo, Federico ^a   Moro Sibilot, Denis ^b   Gautschi, Oliver ^c   Boleti, Ekaterini ^d   Felip, Enriqueta ^e   Groen, Harry J M ^f   Germonpré, Paul ^g   Meldgaard, Peter ^h   Arriola, Edurne ⁱ   Steele, Nicola ^j   Fox, Jesme ^k   Schnell, Patrick ^l   Engelsberg, Arne ^m   Wolf, Jürgen ⁿ  

^a ISTITUTO TOSCANO TUMORI   (Italy)

^b HÔPITAL MICHALLON   (France)

^c LUZERNER KANTONSSPITAL   (Switzerland)

^d ROYAL FREE HOSPITAL   (United Kingdom)

^e HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^f UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^g AZ Maria Middelares   (Belgium)

^h AARHUS UNIVERSITY HOSPITAL   (Denmark)

ⁱ HOSPITAL DEL MAR   (Spain)

^j BEATSON WEST OF SCOTLAND CANCER CENTRE   (United Kingdom)

^k The Roy Castle Lung Cancer Foundation   (United Kingdom)

^l Pfizer Ltd   (United States)

^m PFIZER INC   (United States)

ⁿ UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

more..

Author keywords

Anaplastic lymphoma kinase (ALK) inhibitor; Crizotinib; Non small cell lung cancer (NSCLC); Safety profile; Therapy management; Treatment beyond progression

Indexed keywords

ANAPLASTIC LYMPHOMA KINASE; CRIZOTINIB; ANTINEOPLASTIC AGENT; PROTEIN KINASE INHIBITOR; PROTEIN TYROSINE KINASE; PYRAZOLE DERIVATIVE; PYRIDINE DERIVATIVE;

CANCER GROWTH; CARDIOTOXICITY; CONSTIPATION; DIARRHEA; DRUG SAFETY; EDEMA; FATIGUE; GENE REARRANGEMENT; HUMAN; HYPERTRANSAMINASEMIA; HYPOGONADISM; LIVER TOXICITY; MEDICATION THERAPY MANAGEMENT; NAUSEA; NON SMALL CELL LUNG CANCER; PRIORITY JOURNAL; REVIEW; TREATMENT DURATION; VISUAL DISORDER; VOMITING; CARCINOMA, NON-SMALL-CELL LUNG; CLINICAL TRIAL (TOPIC); DISEASE MANAGEMENT; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; GENE TRANSLOCATION; GENETICS; LUNG NEOPLASMS;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; CLINICAL TRIALS AS TOPIC; DISEASE MANAGEMENT; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; HUMANS; LUNG NEOPLASMS; PROTEIN KINASE INHIBITORS; PYRAZOLES; PYRIDINES; RECEPTOR PROTEIN-TYROSINE KINASES; TRANSLOCATION, GENETIC;

EID: 84922571357     PISSN: 01695002     EISSN: 18728332     Source Type: Journal    
DOI: 10.1016/j.lungcan.2014.12.010     Document Type: Review

References (42)

1. Rikova K., Guo A., Zeng Q., et al. Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer. Cell 2007, 131:1190-1203.
2. Soda M., Choi Y.L., Enomoto M., et al. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature 2007, 448:561-566.
3. Soda M., Takada S., Takeuchi K., et al. A mouse model for EML4-ALK-positive lung cancer. Proc Natl Acad Sci USA 2008, 105:19893-19897.
4. Kwak E.L., Bang Y.J., Camidge D.R., et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med 2010, 363:1693-1703.
5. Zou H.Y., Li Q., Lee J.H., et al. An orally available small-molecule inhibitor of c-Met, PF-2341066, exhibits cytoreductive antitumor efficacy through antiproliferative and antiangiogenic mechanisms. Cancer Res 2007, 67:4408-4417.
6. Bergethon K., Shaw A.T., Ou S.H., et al. ROS1 rearrangements define a unique molecular class of lung cancers. J Clin Oncol 2012, 30:863-870.
7. Christensen J.G., Zou H.Y., Arango M.E., et al. Cytoreductive antitumor activity of PF-2341066, a novel inhibitor of anaplastic lymphoma kinase and c-Met, in experimental models of anaplastic large-cell lymphoma. Mol Cancer Ther 2007, 6:3314-3322.
8. Pfizer Inc. EU Xalkori (crizotinib) summary of product characteristics 2014, Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002489/WC500134759.pdf [accessed 23.04.14].
9. Reck M., Popat S., Reinmuth N., et al. Metastatic non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2014, 25(Suppl. 3):iii27-iii39.
10. Ettinger D.S., Akerley W., Borghaei H., et al. Non-small cell lung cancer. J Natl Compr Cancer Netw 2012, 10:1236-1271.
11. Camidge D.R., Bang Y., Kwak E.L., et al. Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study. Lancet Oncol 2012, 13:1011-1019.
12. Kim D.-W., Ahn M.-J., Shi Y., et al. Results of a global phase II study with crizotinib in advanced ALK-positive non-small cell lung cancer (NSCLC). Poster presented at the 48th annual meeting of the American society of clinical oncology (ASCO) 2012, [Abstract 7533].
13. Blackhall F., Evans T.L., Han J.-Y., et al. Impact of crizotinib treatment on patient-reported symptoms and quality of life in advanced ALK-positive non-small cell lung cancer 2012, Poster presented at the European Society of Medical Oncology (ESMO), Vienna, Austria, September 28-October 2, [Abstract 1231PD].
14. Shaw A.T., Kim D.W., Nakagawa K., et al. Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. N Engl J Med 2013, 368:2385-2394. [and supplemental material].
15. Mok T., Kim D.-W., Wu Y.-L., et al. First-line crizotinib versus pemetrexed-cisplatin or pemetrexed-carboplatin in patients (pts) with advanced ALK-positive non-squamous non-small cell lung cancer (NSCLC): results of a phase III study (PROFILE 1014). J Clin Oncol 2014, 32(May (Suppl. 20)). [Abstract 8002].
16. Solomon B., Felip E., Blackhall F.H., et al. Overall and intracranial (IC) efficacy results and time to symptom deterioration in PROFILE 1014: 1st-line crizotinib vs pemetrexed-platinum chemotherapy (PPC) in patients (pts) with advanced ALK-positive non-squamous non-small cell lung cancer (NSCLC). Ann Oncol 2014, 25(Suppl. 4):iv427. [Abstract 1225O].
17. Ou S.H., Tong W.P., Azada M., et al. Heart rate decrease during crizotinib treatment and potential correlation to clinical response. Cancer 2013, 119:1969-1975.
18. Schnell P., Wilner K., Bartlett C.H., et al. Clinical presentation of hepatotoxicity-associated with crizotinib in ALK-positive (ALK+) advanced non-small cell lung cancer (NSCLC) 2012, Poster presented at the American Society of Clinical Oncology (ASCO), Chicago, IL, USA, June 1-5, [Abstract 7598].
19. Weickhardt A.J., Rothman M.S., Salian-Mehta S., et al. Rapid-onset hypogonadism secondary to crizotinib use in men with metastatic nonsmall cell lung cancer. Cancer 2012, 118:5302-5309.
20. Solomon B., Chiappori A., Lamb A., et al. Preliminary characterization of visual events reported by patients receiving crizotinib for the treatment of advanced ALK-positive non-small cell lung cancer. Poster presented at the European multidisciplinary cancer congress 2011, [Abstract 3030].
21. Besse B., Salgia R., Solomon B., et al. Visual disturbances in patients (pts) with anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC) treated with crizotinib. Poster presentation at the European society of medical oncology (ESMO) annual meeting 2012, [Abstract 1268P].
22. Matsumoto D., Liu C.-N., Somps C., et al. Effect of retinal function as a mechanism of vision disorders with crizotinib. Poster presented at the 101st annual meeting of the American association for cancer research (AACR) 2010, [Abstract 4385].
23. Mellor H.R., Bell A.R., Valentin J.P., et al. Cardiotoxicity associated with targeting kinase pathways in cancer. Toxicol Sci 2011, 120:14-32.
24. Pfizer Inc. Xalkori prescribing information November 2013, US Food and Drug Administration, Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/202570s000lbl.pdf [accessed 5.02.14].
25. National Cancer Institute (NCI) National Cancer Institute common terminology criteria for adverse events v4.0 2009, NCI, NIH, DHHS, [May 29, 2009; NIH publication #09-7473].
26. Weickhardt A.J., Doebele R.C., Purcell W.T., et al. Symptomatic reduction in free testosterone levels secondary to crizotinib use in male cancer patients. Cancer 2013, 119:2383-2390.
27. Vigen R., O'Donnell C.I., Baron A.E., et al. Association of testosterone therapy with mortality, myocardial infarction, and stroke in men with low testosterone levels. JAMA 2013, 310:1829-1836.
28. Brosnan E.M., Weickhardt A.J., Lu X., et al. Drug-induced reduction in estimated glomerular filtration rate in patients with ALK-positive non-small cell lung cancer treated with the ALK inhibitor crizotinib. Cancer 2014, 120:664-674.
29. Doebele R.C., Pilling A.B., Aisner D.L., et al. Mechanisms of resistance to crizotinib in patients with ALK gene rearranged non-small cell lung cancer. Clin Cancer Res 2012, 18:1472-1482.
30. Katayama R., Shaw A.T., Khan T.M., et al. Mechanisms of acquired crizotinib resistance in ALK-rearranged lung cancers. Sci Transl Med 2012, 4:120ra17.
31. Kim S., Kim T.M., Kim D.W., et al. Heterogeneity of genetic changes associated with acquired crizotinib resistance in ALK-rearranged lung cancer. J Thorac Oncol 2013, 8:415-422.
32. Zhang S., Wang F., Keats J., et al. Crizotinib-resistant mutants of EML4-ALK identified through an accelerated mutagenesis screen. Chem Biol Drug Des 2011, 78:999-1005.
33. Chaft J.E., Oxnard G.R., Sima C.S., et al. Disease flare after tyrosine kinase inhibitor discontinuation in patients with EGFR-mutant lung cancer and acquired resistance to erlotinib or gefitinib: implications for clinical trial design. Clin Cancer Res 2011, 17:6298-6303.
34. Pop O., Pirvu A., Toffart A.-C., et al. Disease flare after treatment discontinuation in a patient with EML4-ALK lung cancer and acquired resistance to crizotinib. J Thorac Oncol 2012, 7:e1-e2.
35. Kuriyama Y., Kim Y.H., Nagai H., et al. Disease flare after discontinuation of crizotinib in anaplastic lymphoma kinase-positive lung cancer. Case Rep Oncol 2013, 6:430-433.
36. Gan G.N., Weickhardt A.J., Scheier B., et al. Stereotactic radiation therapy can safely and durably control sites of extra-central nervous system oligoprogressive disease in anaplastic lymphoma kinase-positive lung cancer patients receiving crizotinib. Int J Radiat Oncol Biol Phys 2014, 88:892-898.
37. Weickhardt A.J., Scheier B., Burke J.M., et al. Local ablative therapy of oligoprogressive disease prolongs disease control by tyrosine kinase inhibitors in oncogene-addicted non-small-cell lung cancer. J Thorac Oncol 2012, 7:1807-1814.
38. Ou S.H., Janne P.A., Bartlett C.H., et al. Clinical benefit of continuing ALK inhibition with crizotinib beyond initial disease progression in patients with advanced ALK-positive NSCLC. Ann Oncol 2014, 25:415-422.
39. Takeda M., Okamoto I., Nakagawa K. Clinical impact of continued crizotinib administration after isolated central nervous system progression in patients with lung cancer positive for ALK rearrangement. J Thorac Oncol 2013, 8:654-657.
40. Shaw A.T., Kim D.W., Mehra R., et al. Ceritinib in ALK-rearranged non-small-cell lung cancer. N Engl J Med 2014, 370:1189-1197.
41. Gadgeel S.M., Gandhi L., Riely G.J., et al. Safety and activity of alectinib against systemic disease and brain metastases in patients with crizotinib-resistant ALK-rearranged non-small-cell lung cancer (AF-002JG): results from the dose-finding portion of a phase 1/2 study. Lancet Oncol 2014, 15:1119-1128.
42. Browning E.T., Weickhardt A.J., Camidge D.R. Response to crizotinib rechallenge after initial progression and intervening chemotherapy. J Thorac Oncol 2013, 8:e21.